- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3753
| Related Targets | PI3K Akt GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK |
|---|---|
| Other mTOR Products | Torin 1 Torin 2 AZD8055 Ridaforolimus (Deforolimus, MK-8669) Sapanisertib (INK-128) Torkinib (PP242) Vistusertib (AZD2014) MHY1485 KU-0063794 OSI-027 |
|
In vitro |
Water : 13 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 131.17 | Formula | C6H13NO2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 61-90-5 | -- | Storage of Stock Solutions |
|
|
| Synonyms | (S)-Leucine, Leu | Smiles | CC(C)CC(C(=O)O)N | ||
| In vitro |
Leucine also stimulates protein synthesis in muscle and is closely associated with the release of gluconeogenic precursors, such as alanine, from muscle.
|
|---|---|
| In vivo |
Leucine has a half-life of 45 minutes.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05621291 | Recruiting | B-All|Acute Lymphoblastic Leukemia |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
May 15 2024 | Not Applicable |
| NCT06340685 | Recruiting | Pyruvate Dehydrogenase Complex Deficiency |
Jirair Krikor Bedoyan|Ultragenyx Pharmaceutical Inc|University of Pittsburgh |
May 2024 | Phase 1 |
| NCT06256744 | Not yet recruiting | Dietary Supplementation|Exercise |
Brock University|University of Toronto |
March 2024 | Not Applicable |
| NCT06050668 | Not yet recruiting | Femoral Fracture|Fragility Fracture|Muscle Atrophy |
Michael C Willey|MEND|University of Iowa |
February 2024 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.